Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy

FOLKERT J. TENCATE, M.D., PATRICK W. SERRUYS, M.D., SIMON MEY, MSc, and JOS ROELANDT, M.D.

ABSTRACT The effects of short-term administration of verapamil on left ventricular isovolumetric relaxation and early and late diastolic filling dynamics were studied in 10 patients with hypertrophic cardiomyopathy by a combined hemodynamic-ultrasonic technique. Left ventricular pressures (recorded with high-fidelity micromanometers) were determined simultaneously with M-mode echocardiography. After 10 mg of verapamil was given intravenously (2 mg/min), left ventricular contractility and systolic pressure dropped significantly (p < .05). Left ventricular dP/dt fell from 1947 ± 544 to 1489 ± 334 mm Hg/sec, maximal velocity of the contractile element at zero load fell from 50 ± 17 to 42 ± 15 1/sec, peak velocity contraction of the contractile element fell from 37 ± 10 1/sec to 29 ± 10 1/sec (p < .05), and left ventricular systolic pressure fell from 149 ± 30 to 127 ± 22 mm Hg. Left ventricular negative dP/dt increased from 1770 ± 479 to 1477 ± 377 mm Hg/sec (p < .05), and the time constant of isovolumetric pressure decay was prolonged from 48 ± 9 to 64 ± 15 msec (p < .05). Left ventricular end-diastolic pressure rose from 21 ± 7 to 23 ± 6 mm Hg (p < .05). The time constant of isovolumetric pressure decay was calculated in three different ways, but none of these measurements was influenced by verapamil. Time of isovolumetric relaxation, duration of rapid ventricular filling, and peak rate of left ventricular lengthening were not significantly influenced by verapamil and remained highly abnormal. In contrast, peak rate of left ventricular posterior wall thickening declined further after verapamil from 2.9 ± 1.2 to 2.4 ± 1.4 1/sec (p < .05). The constructed pressure-dimension loops did not show any change after verapamil. Plasma levels of verapamil in eight of the 10 patients were in the therapeutic range (im: 90 to 180 ng/ml); heart rate did not change. Our data indicate that abnormal relaxation and disturbed filling dynamics of the left ventricle persisted after short-term administration of verapamil. Further studies in well-defined subgroups of patients after long-term oral treatment with verapamil are needed to establish the merits of medical treatment of hypertrophic cardiomyopathy.

Circulation 68, No. 6, 1274–1279, 1983.

SEVERAL authors have described a beneficial effect of verapamil on left ventricular diastolic filling and relaxation in patients with hypertrophic cardiomyopathy using different methods after both intravenous and oral administration of the drug. It has been proposed from their findings that verapamil probably increases left ventricular "distensibility" in patients with this disease. However, a direct pressure-dimension relationship could not be constructed from the presented data of either study. Therefore, we undertook a study using high-fidelity pressure measurements and M-mode echocardiography simultaneously to assess the short-term effects of verapamil on left ventricular relaxation and filling. To our knowledge, this method has not been used before to determine the effects of verapamil in patients with hypertrophic cardiomyopathy.
Methods

Patients. Ten patients with hypertrophic cardiomyopathy were studied (five men and five women, mean age 42.2 years) with M mode echocardiography (Echo-cardiovisor; Or ganon Teknika) and right and left cardiac catheterization (table 1). The diagnosis of hypertrophic cardiomyopathy was based on combined echocardiographic, angiographic, and hemodynamic evaluation. Echocardiography revealed that all patients had hypertrophied nondilated left ventricles without having any other acquired or congenital heart disease. All of them had a disproportionate increase of the interventricular septum compared with the left ventricular posterior wall (ratio of interventricular septum to posterior wall ≥1.3), decreased systolic septal thickening (25% or less), and an abnormal left ventricular shape on two-dimensional echocardiographic imaging.

Two-dimensional echocardiography revealed that left ventricular hypertrophy involved substantial portions of both the interventricular septum and left ventricular free wall.

Left heart catheterization demonstrated a systolic pressure gradient in five patients at baseline, whereas one patient exhibited a gradient on provocation with the Valsalva maneuver. In the five patients with a systolic pressure gradient at baseline, this gradient increased after provocation by Valsalva maneuver or by atrial pacing.

No provocative tests were performed in one patient with a systolic pressure gradient of 104 mm Hg at baseline. The other patients did not exhibit a gradient at baseline or under provocation.

All drug treatment was discontinued at least 48 hr before our study of the effects of verapamil was undertaken. None of the patients had been treated by verapamil before. All patients were functionally limited at the time of study despite treatment with propranolol (mean dosage 160 ± 40 mg/day). Nine of them were in functional class II and one was in functional class III according to criteria of the New York Heart Association.

Selection for the present study was based on lack of improvement of symptoms when treated with propranolol and, therefore, the patients were considered for treatment with verapamil or for surgery.

Informed consent was obtained from all patients.

Cardiac catheterization and angiography. All patients underwent cardiac catheterization, which included complete hemodynamic evaluation, cineangiography of the left ventricle, and selective coronary arteriography by Sones’ technique. Coronary arteriograms were judged by two independent observers. Resting gradients across the left ventricular outflow tract were determined by simultaneous registrations of left ventricular pressures by two tip-micromanometers (No. 7F; Millar) while one catheter was pulled back slowly under continuous fluoroscopy; left ventricular dP/dt (both positive and negative), maximal velocity of the contractile element at zero load (V_max), and peak velocity contraction of the contractile element (peak Velocity) were calculated on-line with an automated data processing system, which has been described earlier. The time constant of isovolumetric pressure decay was measured after completion of the study from the left ventricular pressure tracings. This was done by plotting the natural logarithm of pressure against time after peak negative dP/dt. The time constant was calculated as the slope of this monoexponential curve during the first 40 msec after peak negative dP/dt (T_1). The data obtained after the first 40 msec and until the level of the left ventricular end-diastolic pressure of the preceding beat were plotted the same way as for T_1 and revealed T_2. Also, when the asymptote (P_0) of the monoexponential relationship of pressure against time was calculated by the formula P(t) = P_0 e^{-t/T_2} + P_b, T_1 was found (P_0 = pressure at t = 0; t = time). The method for calculation of this time constant of relaxation has been described in detail elsewhere.

Provocative tests included a stress test of atrial pacing in incremental steps of 10 beats/min and the Valsalva maneuver. Left ventricular cineangiograms were recorded in the right and left anterior oblique projections to assess the presence of mitral incompetence. Reference levels for zero pressure measurements were taken at mid thorax and were adjusted when necessary during the procedure by use of the fluid channel of the tip-micromanometer. The study of verapamil and its effect on left ventricular filling dynamics and relaxation was carried out as follows: left ventricular pressures, aortic pressures, left ventricular dP/dt, and electrocardiograms (three standard limb leads) were recorded on paper at high (200 mm/sec) and low speed as necessary. Left ventricular pressure and aortic pressure were determined simultaneously with the recording of electrocardiograms and M mode echocardiograms during baseline (control), during 5 min of verapamil infusion (2 mg/min), and for 15 min after completion of administration of the drug. Immediately after completion of the study, blood samples were drawn for determination of plasma levels of verapamil.

Echocardiography. M mode echocardiograms of the left ventricle were made in all patients at a paper speed of 50 mm/sec. We used a 0.5 inch diameter, 2.25 MHz transducer focused at 7.5 cm. The M mode echocardiograms were recorded in a standard fashion we described earlier. Briefly, during examination with the patient in the supine or slightly lateral decubitus position, several M mode sector scans were taken from the level of the aortic root across the left ventricular cavity to the left ventricular apex. The transducer was placed on the chest wall and was held perpendicularly when the largest amplitude of motion of the anterior mitral leaflet was recorded. The M mode echocardiograms of the left ventricle were always obtained at a level just below the tips of both mitral leaflets, and gain settings were continuously adjusted to obtain optimal resolution of endocardial surfaces of both interventricular septum and left ventricular posterior wall. The left ventricular and aortic pressures were recorded simultaneously with the recording of M mode echocardiograms and electrocardiograms.

To analyze the same beats for left ventricular pressures and echocardiograms, "precise" timing by zero-calibration markers was used (see figure 1).

After completion of the study of the effects of verapamil, two-dimensional echocardiographic studies were performed for all patients with a Toshiba SSH-10A phased-array sector scanner with a 2.25 MHz transducer. These studies were obtained from the same position as the M mode transducer in a plane parallel to the long-axis of the left ventricle and by tilting the transducer 90 degrees for the short-axis cross section. This examination technique to obtain short-axis cross sections from various levels of the left ventricle for the determination of the extent and distribution of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy has been described in detail elsewhere.

All our patients showed extensive left ventricular hypertrophy involving substantial portions of the interventricular septum and left ventricular free wall that was comparable to group III left ventricular hypertrophy described by Maron et al. Two-dimensional echocardiographic analysis therefore indicated that area of the posterior wall, as examined by M mode echocardiography, was involved in the hypertrophic (or cardiomyopathic) process.

Analysis of M mode echocardiograms. Earlier data of our laboratory show that in patients with hypertrophic cardiomyopathy, both rates of systolic thickening and thinning of the interventricular septum are reduced when compared with that of normal subjects (peak thinning rate: normal, 3.0 ± 1.3 sec^-1; hypertrophic cardiomyopathy, 1.2 ± 0.6 sec^-1; p < .005). Normal values for rates of peak lengthening (3.4 ± 0.6 sec^-1)
CARDIAC CYCLE TIMES 

The cardiac cycle can be divided into two periods: isovolumetric contraction and isovolumetric relaxation. The isovolumetric contraction period is the time from the onset of ventricular systole (QRS complex) to the opening of the mitral valve, which is approximately 0.05 seconds. The isovolumetric relaxation period is the time from the opening of the mitral valve to the end of diastole, which is approximately 0.10 seconds.

Aortic valve opening (AVO) occurs after the mitral valve opens, and aortic valve closure (AVC) occurs after the mitral valve closes. The aortic valve opens approximately 0.05 seconds after the mitral valve opens, and it closes approximately 0.05 seconds after the mitral valve closes.

Aortic valve opening occurs before the mitral valve opening, but after the atrioventricular conduction delay, which is approximately 0.02 seconds.

In summary, the cardiac cycle consists of the following events:

1. atrial systole
2. ventricular systole
3. isovolumetric contraction
4. isovolumetric relaxation
5. aortic valve opening
6. aortic valve closure
7. ventricular filling
8. atrial filling

The cardiac cycle is typically divided into the following phases:

- **Systole**: The period from atrial systole to ventricular diastole.
- **Diastole**: The period from ventricular diastole to atrial systole.

During systole, the heart contracts, and blood is pumped from the ventricles into the arteries. During diastole, the heart relaxes, and blood is returned to the heart from the veins.

The intraventricular septum and the posterior wall of the left ventricle are the primary components of the heart wall. The thickness of these walls is important in determining the pressure and volume of blood within the ventricles.

**Pressure-Dimension Loops**

Pressure-dimension loops are graphs that show the relationship between pressure and ventricular volume during the cardiac cycle. These loops are useful in assessing the cardiac function and diagnosing cardiac diseases.

**Statistical Analysis**

Statistical analysis is used to determine the significance of the results obtained from the cardiac cycle measurements. It is important to consider the sample size and the variability of the data when interpreting the results.

**Results**

The clinical and hemodynamic features of our patients are shown in Table 1. Coronary arteriograms were normal in all.

In the five patients with a systolic pressure gradient at baseline (patient Nos. 2, 3, 7, 8, and 9), the magnitude of this gradient did not change in one (patient 3), decreased from 85 mm Hg to 70 mm Hg in patient 2, and decreased from 90 mm Hg to 80 mm Hg in patient 8. The systolic pressure gradient was abolished in pa-
TABLE 1

Clinical and hemodynamic features

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Validity</th>
<th>LV-Ao gradient (mm Hg)</th>
<th>LVEDP (mm Hg)</th>
<th>Provenation</th>
<th>Heart rate</th>
<th>Mitral incompetence</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>51</td>
<td>M</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>15</td>
<td>Grade I</td>
</tr>
<tr>
<td>2</td>
<td>55</td>
<td>M</td>
<td>II</td>
<td>85</td>
<td>145</td>
<td>33</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>47 F</td>
<td>II/II</td>
<td>76</td>
<td>124</td>
<td>22</td>
<td>Grade I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>30 M</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>20</td>
<td>Grade II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>54 F</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>24</td>
<td>Grade II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>55 M</td>
<td>II</td>
<td>0</td>
<td>45</td>
<td>19</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>27 M</td>
<td>II</td>
<td>70</td>
<td>140</td>
<td>10</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>33 F</td>
<td>II</td>
<td>90</td>
<td>120</td>
<td>12</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>30 F</td>
<td>II</td>
<td>104</td>
<td>No pro...</td>
<td>29</td>
<td>Grade I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>45 F</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>18</td>
<td>Grade I</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LV = left ventricular; Ao = aorta; LVEDP = left ventricular end-diastolic pressure.

Validity is judged according to New York Heart Association criteria.

Patient 7. In one patient (No. 9), this gradient increased from 104 to 200 mm Hg with a simultaneous drop in systemic systolic blood pressure from 95 to 50 mm Hg.

Pressure-derived measurements. Tables 2A and 2B show the results of the pressure-derived contraction and relaxation parameters before and after administration of verapamil. Table 2A shows that left ventricular end-diastolic pressure rose significantly from 21 ± 7 to 23 ± 6 mm Hg after verapamil (p < .05). In all patients a slight but significant decrease in systolic systemic pressure (from 120 ± 5 to 100 ± 5 mm Hg (p < .05) was seen. In addition, left ventricular contractility decreased, as can be seen from the various parameters that were determined: positive left ventricular dP/dt, V max, and peak V ce. Table 2B shows that negative left ventricular dP/dt significantly increased (p < .05) after verapamil, and the time constant of relaxation was significantly prolonged. It is also evident from Table 2B that various measurements of the time constant did not change after verapamil.

Ultrasound-derived measurements. The echocardiographic measurements before and after verapamil are shown in tables 3A and 3B. It is apparent that left ventricular dimensions and wall thicknesses at both end-diastole and end-systole were not influenced by verapamil. Also, fractional shortening and myocardial thickening were not changed. Although rate of left ventricular lengthening was not changed, peak rate of left ventricular posterior wall thinning decreased significantly from 2.9 ± 1.2 to 2.4 ± 1.4 sec⁻¹ (p < .05). Other parameters of diastolic function such as isovolumetric relaxation time, rapid filling period, and t max dD/dt did not change either. None of the pressure-dimension loops for the patients shows any change compatible with an improved distensibility at any point in the cardiac cycle. Figure 2 shows a characteristic example of a pressure-dimension loop (patient 8); a leftward or upward diastolic shift compatible with decreased distensibility is shown. Cycle efficiency changed from 68% to 62% (p = NS) after verapamil.

Blood levels of verapamil. In eight patients plasma levels of verapamil were determined, which varied from 90 to 180 ng/ml (therapeutic range, 60 to 140 ng/ml). In the other two patients, plasma levels of verapamil could not be determined.

Discussion

It has been suggested that the beneficial effects of verapamil treatment are related to an increased left ventricular filling and improved relaxation resulting in an increased distensibility.1–3 Hanrath et al.1 found increased rates of left ventricular lengthening and posterior wall thinning after short-term administration of verapamil. Bonow et al.,2 using radionuclide angiography, showed that peak rate of left ventricular filling increased and time to peak filling was reduced after oral verapamil treatment.
FIGURE 2. Representative pressure-dimension loop. Observe that after verapamil administration (solid line) the pressure-dimension loop has shifted leftward and upward for its diastolic portion, indicating decreased "distensibility." Ao = aortic valve closure determined from aortic pressure recording; MV = mitral valve opening determined from the echocardiogram. Broken line represents pressure-dimension loop before verapamil administration.

In contrast to these studies, we were not able to demonstrate an improvement in left ventricular relaxation nor filling after short-term administration of verapamil. This was true even though an effective dosage was achieved as demonstrated by the drop in left ventricular systolic pressures and contractility.

During early diastole, when left ventricular pressures and left ventricular dimensions were changing rapidly, both rates of relaxation and regional thinning were further impaired. Moreover, left ventricular end-diastolic pressure increased without a change in left ventricular dimension, indicating decreased distensibility.

These effects cannot be completely attributed to our patient selection because the relevant hemodynamic

<table>
<thead>
<tr>
<th>TABLE 3A</th>
<th>Ultrasound-derived measurements before and after verapamil</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
</tr>
<tr>
<td>LVED (mm)</td>
<td>37.6±4.1</td>
</tr>
<tr>
<td>LVES (mm)</td>
<td>24.0±5.5</td>
</tr>
<tr>
<td>Peak rate of shortening (l/sec)</td>
<td>2.6±0.9</td>
</tr>
<tr>
<td>LVPW&lt;sub&gt;ED&lt;/sub&gt; (mm)</td>
<td>14.1±2.1</td>
</tr>
<tr>
<td>LVPW&lt;sub&gt;ES&lt;/sub&gt; (mm)</td>
<td>20.3±4.5</td>
</tr>
<tr>
<td>Peak rate of thickening (l/sec)</td>
<td>2.3±0.7</td>
</tr>
</tbody>
</table>

LVED = left ventricular end-diastolic dimension; LVES = left ventricular end-systolic dimension; LVPW = left ventricular posterior wall.

data (left ventricular end-diastolic pressure and subvalvular left ventricular gradient) did not suggest that the disease was in a late stage (see table 1). However, analysis by two-dimensional echocardiography showed extensive left ventricular hypertrophy involving substantial portions of the interventricular septum and left ventricular free wall. Furthermore, the absolute end-diastolic posterior wall thickness was increased in all as determined by M mode echocardiography, and rates of posterior wall thinning were low, suggesting that magnitude of thickening and a decreased regional myocardial diastolic function were present.

Although our methodology is state of the art, several strong limitations are present that should be discussed before tentative conclusions are drawn. Beat-to-beat variations of both M mode echocardiograms and of the time constant can be substantial. Since we recorded left ventricular pressures and M mode echocardiograms simultaneously, we avoided analyzing those beats where large variations in these parameters due to technical inadequacies or respiration were found. Moreover, intraobserver and interobserver variability of the echocardiographic measurements and beat-to-beat variation of indexes derived by echocardiography were small and comparable with current findings in the literature.

The M mode echocardiogram has specific limitations and is therefore not suitable to detect global changes in left ventricular function. This is illustrated by our findings, because significant changes in left ventricular contractility as seen by the pressure-derived measurements of contractility could not be determined from the echocardiogram. On the other hand, the method can be used to detect regional changes in left ventricular function. This is shown by decreased rates of posterior wall thinning after verapamil and is supported by a concomitant increase in the time constant of isovolumetric relaxation and a decrease in neg-

TABLE 3B

<table>
<thead>
<tr>
<th>TABLE 3B</th>
<th>Ultrasound-derived measurements before and after verapamil</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
</tr>
<tr>
<td>LVID peak rate of lengthening (l/sec)</td>
<td>3.4±1.1</td>
</tr>
<tr>
<td>LVPW peak rate of thinning (l/sec)</td>
<td>2.9±1.2</td>
</tr>
<tr>
<td>Isovolumetric relaxation time (msec)</td>
<td>79±28</td>
</tr>
<tr>
<td>Rapid filling period (msec)</td>
<td>96±27</td>
</tr>
<tr>
<td>t max dD/dt (msec)</td>
<td>120±12</td>
</tr>
</tbody>
</table>

LVID = left ventricular internal dimension; LVPW = left ventricular posterior wall. For further explanation of abbreviations see text.
ative left ventricular dP/dt. Because, to our knowledge, this is the first study that has used this method to study the effects of verapamil in patients with hypertrophic cardiomyopathy, no comparison is available with respect to the relationship of the time constant of relaxation and rates of posterior wall thinning.

Our results are probably not entirely comparable with results described after oral verapamil treatment, because in the present short-term study a significant drop in left ventricular contractility occurred that was not present in other studies. Tissue distribution of verapamil after oral treatment is probably different from that after short-term administration. Thus, although we reached therapeutic plasma levels in our patients, these levels probably bear no relationship to plasma levels reached after long-term oral treatment.

The heterogeneous aspects of hypertrophic cardiomyopathy, both in its clinical and hemodynamic expression as in the presence of left ventricular hypertrophy in various areas of the left ventricle and the presence of variations in regional systolic wall thickening in normal subjects of 10% or more make it more difficult to compare our results with findings of others.

Finally, it should be remembered that before verapamil became available, an increased distensibility was found that explained the symptomatic improvement of patients with hypertrophic cardiomyopathy treated with β-blocking drugs. But a recent study that used methods comparable to ours have convincingly shown that diastolic pressure-volume relationships were not influenced by β-blockade and that the earlier observations therefore were not correct.

Despite the limitations of the study as described above, several of our findings support our belief that the area of left ventricular myocardium we studied is involved in the hypertrophic (or cardiomyopathic) process. Individual values of end-diastolic posterior wall thickness as determined by M mode echocardiography varied between 13 and 18 mm and were significantly larger than normal values. Furthermore, two-dimensional echocardiographic analysis with a recently evolved method described by Maron et al. showed that all our patients had extensive left ventricular hypertrophy, which could have been underestimated by M mode echocardiography. Peak rate of lengthening and peak rate of posterior wall thinning were significantly (p < .05) lower than those for normal subjects in our laboratory, suggesting a depressed regional myocardial diastolic function.

Thus, our observations show no improvement in left ventricular diastolic function after short-term administration of verapamil. These results therefore support clinical observations that potential complications after oral verapamil treatment might occur due to systemic hypotension and decreased contractility. Extrapo-

lation of our results to clinical management should be carried out with caution because of the short-term nature of this study.

We greatly appreciate the technical support of Harald TenKaten, Gerard van Zwieten, and Hans Eggink, and the statistical advice of Ron Brower, Ph.D. Knoll Nederland BV Mydrecht is acknowledged for providing determination of plasma levels of verapamil.

References
Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy.
F J TenCate, P W Serruys, S Mey and J Roelandt